Garth Powis

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Living Beings

Anatomy

Physiology

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Koh Mei Yee; Spivak-Kroizman Taly R; Powis Garth
Inhibiting the hypoxia response for cancer therapy: the new kid on the block.
Moses Sylvestor A; Ali M Ahad; Zuohe Song; Du-Cuny Lei; Zhou Li Li; Lemos Robert; Ihle Nathan; Skillman A Geoffrey; Zhang Shuxing; Mash Eugene A; Powis Garth; Meuillet Emmanuelle J
In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT.
Koh Mei Yee; Powis Garth
HAF : the new player in oxygen-independent HIF-1alpha degradation.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Garth Powis (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Koh Mei Yee; Spivak-Kroizman Taly R; Powis Garth
Inhibiting the hypoxia response for cancer therapy: the new kid on the block.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(19):5945-6.
2009: Moses Sylvestor A; Ali M Ahad; Zuohe Song; Du-Cuny Lei; Zhou Li Li; Lemos Robert; Ihle Nathan; Skillman A Geoffrey; Zhang Shuxing; Mash Eugene A; Powis Garth; Meuillet Emmanuelle J
In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT.
Cancer research 2009;69(12):5073-81.
2009: Koh Mei Yee; Powis Garth
HAF : the new player in oxygen-independent HIF-1alpha degradation.
Cell cycle (Georgetown, Tex.) 2009;8(9):1359-66.
2009: Schwartz David L; Powis Garth; Thitai-Kumar Arun; He Yi; Bankson James; Williams Ryan; Lemos Robert; Oh Junghwan; Volgin Andrei; Soghomonyan Suren; Nishii Ryuichi; Alauddin Mian; Mukhopadhay Uday; Peng Zhenghong; Bornmann William; Gelovani Juri
The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects.
Molecular cancer therapeutics 2009;8(4):947-58.
2009: James Brian P; Staatz William D; Wilkinson Sarah T; Meuillet Emmanuelle; Powis Garth
Superoxide dismutase is regulated by LAMMER kinase in Drosophila and human cells.
Free radical biology & medicine 2009;46(6):821-7.
2009: Powis Garth; Ihle Nathan T; Yung W K Alfred
Inhibiting PI-3-K for glioma therapy.
Cell cycle (Georgetown, Tex.) 2009;8(3):335.
2009: Ihle Nathan T; Lemos Robert; Schwartz David; Oh Junghwan; Halter Robert J; Wipf Peter; Kirkpatrick Lynn; Powis Garth
Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity.
Molecular cancer therapeutics 2009;8(1):94-100.
2009: Ihle Nathan T; Powis Garth
Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy.
Molecular cancer therapeutics 2009;8(1):1-9.
2009: Ihle Nathan T; Lemos Robert; Wipf Peter; Yacoub Adly; Mitchell Clint; Siwak Doris; Mills Gordon B; Dent Paul; Kirkpatrick D Lynn; Powis Garth
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.
Cancer research 2009;69(1):143-50.
2008: Koh Mei Yee; Darnay Bryant G; Powis Garth
Hypoxia-associated factor, a novel E3-ubiquitin ligase, binds and ubiquitinates hypoxia-inducible factor 1alpha, leading to its oxygen-independent degradation.
Molecular and cellular biology 2008;28(23):7081-95.
2008: Yee Koh Mei; Spivak-Kroizman Taly R; Powis Garth
HIF-1 regulation: not so easy come, easy go.
Trends in biochemical sciences 2008;33(11):526-34.
2008: Mahadevan Daruka; Powis Garth; Mash Eugene A; George Benjamin; Gokhale Vijay M; Zhang Shuxing; Shakalya Kishore; Du-Cuny Lei; Berggren Margareta; Ali M Ahad; Jana Umasish; Ihle Nathan; Moses Sylvestor; Franklin Chloe; Narayan Satya; Shirahatti Nikhil; Meuillet Emmanuelle J
Discovery of a novel class of AKT pleckstrin homology domain inhibitors.
Molecular cancer therapeutics 2008;7(9):2621-32.
2008: Baker Amanda F; Koh Mei Y; Williams Ryan R; James Brian; Wang Huamin; Tate Wendy R; Gallegos Alfred; Von Hoff Daniel D; Han Haiyong; Powis Garth
Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer.
Pancreas 2008;36(2):178-86.
2008: Koh Mei Y; Spivak-Kroizman Taly; Venturini Sara; Welsh Sarah; Williams Ryan R; Kirkpatrick D Lynn; Powis Garth
Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha.
Molecular cancer therapeutics 2008;7(1):90-100.
2008: Yang Yanan; Iwanaga Kentaro; Raso Maria Gabriela; Wislez Marie; Hanna Amy E; Wieder Eric D; Molldrem Jeffrey J; Wistuba Ignacio I; Powis Garth; Demayo Francesco J; Kim Carla F; Kurie Jonathan M
Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer.
PloS one 2008;3(5):e2220.
2007: Howes Amy L; Chiang Gary G; Lang Elizabeth S; Ho Caroline B; Powis Garth; Vuori Kristiina; Abraham Robert T
The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures.
Molecular cancer therapeutics 2007;6(9):2505-14.
2007: Powis Garth; Kirkpatrick D Lynn
Thioredoxin signaling as a target for cancer therapy.
Current opinion in pharmacology 2007;7(4):392-7.
2007: Baker Amanda F; Landowski Terry; Dorr Robert; Tate Wendy R; Gard Jaime M C; Tavenner Breonna E; Dragovich Tomislov; Coon Amy; Powis Garth
The antitumor agent imexon activates antioxidant gene expression: evidence for an oxidative stress response.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(11):3388-94.
2006: Tatum James L; Kelloff Gary J; Gillies Robert J; Arbeit Jeffrey M; Brown J Martin; Chao K S Clifford; Chapman J Donald; Eckelman William C; Fyles Anthony W; Giaccia Amato J; Hill Richard P; Koch Cameron J; Krishna Murali Cherukuri; Krohn Kenneth A; Lewis Jason S; Mason Ralph P; Melillo Giovanni; Padhani Anwar R; Powis Garth; Rajendran Joseph G; Reba Richard; Robinson Simon P; Semenza Gregg L; Swartz Harold M; Vaupel Peter; Yang David; Croft Barbara; Hoffman John; Liu Guoying; Stone Helen; Sullivan Daniel
Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy.
International journal of radiation biology 2006;82(10):699-757.
2006: Williams Ryan; Baker Amanda F; Ihle Nathan T; Winkler Ashley R; Kirkpatrick Lynn; Powis Garth
The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling.
Cancer chemotherapy and pharmacology 2006;58(4):444-50.
2006: Welsh Sarah J; Koh Mei Yee; Powis Garth
The hypoxic inducible stress response as a target for cancer drug discovery.
Seminars in oncology 2006;33(4):486-97.
2006: Yacoub Adly; Park Margaret A; Hanna David; Hong Young; Mitchell Clint; Pandya Aditi P; Harada Hisashi; Powis Garth; Chen Ching-Shih; Koumenis Costas; Grant Steven; Dent Paul
OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells.
Molecular pharmacology 2006;70(2):589-603.
2006: Powis Garth
Achieving personalized cancer medicine: trials and tribulations.
Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2006;54(5):235-7.
2006: Engman Lars; McNaughton Michael; Gajewska Malgorzata; Kumar Sangit; Birmingham Anne; Powis Garth
Thioredoxin reductase and cancer cell growth inhibition by organogold(III) compounds.
Anti-cancer drugs 2006;17(5):539-44.
2006: Powis Garth; Ihle Nathan; Kirkpatrick D Lynn
Practicalities of drugging the phosphatidylinositol-3-kinase/Akt cell survival signaling pathway.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(10):2964-6.
2006: Powis Garth; Wipf Peter; Lynch Stephen M; Birmingham Anne; Kirkpatrick D Lynn
Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase.
Molecular cancer therapeutics 2006;5(3):630-6.
2006: Baker Amanda F; Dragovich Tomislav; Tate Wendy R; Ramanathan Ramesh K; Roe Denise; Hsu Chiu-Hsieh; Kirkpatrick D Lynn; Powis Garth
The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma.
The Journal of laboratory and clinical medicine 2006;147(2):83-90.
2005: Wipf Peter; Lynch Stephen M; Powis Garth; Birmingham Anne; Englund Erikah E
Synthesis and biological activity of prodrug inhibitors of the thioredoxin-thioredoxin reductase system.
Organic & biomolecular chemistry 2005;3(21):3880-2.
2005: Jordan Bénédicte F; Black Kvar; Robey Ian F; Runquist Matthew; Powis Garth; Gillies Robert J
Metabolite changes in HT-29 xenograft tumors following HIF-1alpha inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo.
NMR in biomedicine 2005;18(7):430-9.
2005: Ihle Nathan T; Paine-Murrieta Gillian; Berggren Margareta I; Baker Amanda; Tate Wendy R; Wipf Peter; Abraham Robert T; Kirkpatrick D Lynn; Powis Garth
The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts.
Molecular cancer therapeutics 2005;4(9):1349-57.
2005: Baker Amanda F; Dragovich Tomislav; Ihle Nathan T; Williams Ryan; Fenoglio-Preiser Cecilia; Powis Garth
Stability of phosphoprotein as a biological marker of tumor signaling.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(12):4338-40.
2005: Jordan Bénédicte F; Runquist Matthew; Raghunand Natarajan; Baker Amanda; Williams Ryan; Kirkpatrick Lynn; Powis Garth; Gillies Robert J
Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478.
Neoplasia (New York, N.Y.) 2005;7(5):475-85.
2005: Jordan Bénédicte F; Runquist Matthew; Raghunand Natarajan; Gillies Robert J; Tate Wendy R; Powis Garth; Baker Amanda F
The thioredoxin-1 inhibitor 1-methylpropyl 2-imidazolyl disulfide (PX-12) decreases vascular permeability in tumor xenografts monitored by dynamic contrast enhanced magnetic resonance imaging.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(2 Pt 1):529-36.
2004: Mustacich Debbie; Wagner Amary; Williams Ryan; Bair Warner; Barbercheck Loretta; Stratton Steven P; Bhattacharyya Achyut K; Powis Garth
Increased skin carcinogenesis in a keratinocyte directed thioredoxin-1 transgenic mouse.
Carcinogenesis 2004;25(10):1983-9.
2004: Meuillet Emmanuelle J; Mahadevan Daruka; Berggren Margareta; Coon Amy; Powis Garth
Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activity.
Archives of biochemistry and biophysics 2004;429(2):123-33.
2004: Ihle Nathan T; Williams Ryan; Chow Sherry; Chew Wade; Berggren Margareta I; Paine-Murrieta Gillian; Minion Daniel J; Halter Robert J; Wipf Peter; Abraham Robert; Kirkpatrick Lynn; Powis Garth
Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling.
Molecular cancer therapeutics 2004;3(7):763-72.
2004: Wipf Peter; Minion Daniel J; Halter Robert J; Berggren Margareta I; Ho Caroline B; Chiang Gary G; Kirkpatrick Lynn; Abraham Robert; Powis Garth
Synthesis and biological evaluation of synthetic viridins derived from C(20)-heteroalkylation of the steroidal PI-3-kinase inhibitor wortmannin.
Organic & biomolecular chemistry 2004;2(13):1911-20.
2004: List Alan F; Glinsmann-Gibson Betty; Stadheim Chad; Meuillet Emmanuelle J; Bellamy William; Powis Garth
Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells.
Experimental hematology 2004;32(6):526-35.
2004: Wipf Peter; Lynch Stephen M; Birmingham Anne; Tamayo Giselle; Jiménez Allan; Campos Nefertiti; Powis Garth
Natural product based inhibitors of the thioredoxin-thioredoxin reductase system.
Organic & biomolecular chemistry 2004;2(11):1651-8.
2004: Powis Garth; Kirkpatrick Lynn
Hypoxia inducible factor-1alpha as a cancer drug target.
Molecular cancer therapeutics 2004;3(5):647-54.
2004: Kaufman Bennett; Scharf Orit; Arbeit Jeffrey; Ashcroft Margaret; Brown J Martin; Bruick Richard K; Chapman J Donald; Evans Sydney M; Giaccia Amato J; Harris Adrian L; Huang Eric; Johnson Randall; Kaelin William; Koch Cameron J; Maxwell Patrick; Mitchell James; Neckers Len; Powis Garth; Rajendran Joseph; Semenza Gregg L; Simons Jonathan; Storkebaum Erik; Welch Michael J; Whitelaw Murray; Melillo Giovanni; Ivy S Percy
Proceedings of the Oxygen Homeostasis/Hypoxia Meeting.
Cancer research 2004;64(9):3350-6.
2004: Welsh Sarah; Williams Ryan; Kirkpatrick Lynn; Paine-Murrieta Gillian; Powis Garth
Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha.
Molecular cancer therapeutics 2004;3(3):233-44.
2004: McNaughton Michael; Engman Lars; Birmingham Anne; Powis Garth; Cotgreave Ian A
Cyclodextrin-derived diorganyl tellurides as glutathione peroxidase mimics and inhibitors of thioredoxin reductase and cancer cell growth.
Journal of medicinal chemistry 2004;47(1):233-9.
2004: Meuillet Emmanuelle J; Ihle Nathan; Baker Amanda F; Gard Jaime M; Stamper Chelsea; Williams Ryan; Coon Amy; Mahadevan Daruka; George Benjamin L; Kirkpatrick Lynn; Powis Garth
In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316.
Oncology research 2004;14(10):513-27.
2003: Welsh Sarah J; Powis Garth
Hypoxia inducible factor as a cancer drug target.
Current cancer drug targets 2003;3(6):391-405.
2003: Engman Lars; Al-Maharik Nawaf; McNaughton Michael; Birmingham Anne; Powis Garth
Thioredoxin reductase and cancer cell growth inhibition by organotellurium compounds that could be selectively incorporated into tumor cells.
Bioorganic & medicinal chemistry 2003;11(23):5091-100.
2003: Watson Walter H; Pohl Jan; Montfort William R; Stuchlik Olga; Reed Matthew S; Powis Garth; Jones Dean P
Redox potential of human thioredoxin 1 and identification of a second dithiol/disulfide motif.
The Journal of biological chemistry 2003;278(35):33408-15.
2003: Raffel Jennifer; Bhattacharyya Achyut K; Gallegos Alfred; Cui Haiyan; Einspahr Janine G; Alberts David S; Powis Garth
Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival.
The Journal of laboratory and clinical medicine 2003;142(1):46-51.
2003: Nonn Larisa; Berggren Margareta; Powis Garth
Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis.
Molecular cancer research : MCR 2003;1(9):682-9.
2003: Husbeck B; Stringer D E; Gerner E W; Powis G
Increased thioredoxin-1 inhibits SSAT expression in MCF-7 human breast cancer cells.
Biochemical and biophysical research communications 2003;306(2):469-75.
2003: Meuillet Emmanuelle J; Mahadevan Daruka; Vankayalapati Hariprasad; Berggren Margareta; Williams Ryan; Coon Amy; Kozikowski Alan P; Powis Garth
Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myo-inositol analogues.
Molecular cancer therapeutics 2003;2(4):389-99.
2003: Welsh Sarah J; Williams Ryan R; Birmingham Anne; Newman David J; Kirkpatrick D Lynn; Powis Garth
The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation.
Molecular cancer therapeutics 2003;2(3):235-43.
2003: Engman Lars; Al-Maharik Nawaf; McNaughton Michael; Birmingham Anne; Powis Garth
Thioredoxin reductase and cancer cell growth inhibition by organotellurium antioxidants.
Anti-cancer drugs 2003;14(2):153-61.
2003: Nonn Larisa; Williams Ryan R; Erickson Robert P; Powis Garth
The absence of mitochondrial thioredoxin 2 causes massive apoptosis, exencephaly, and early embryonic lethality in homozygous mice.
Molecular and cellular biology 2003;23(3):916-22.
2002: Husbeck Bryan; Powis Garth
The redox protein thioredoxin-1 regulates the constitutive and inducible expression of the estrogen metabolizing cytochromes P450 1B1 and 1A1 in MCF-7 human breast cancer cells.
Carcinogenesis 2002;23(10):1625-30.
2002: Welsh Sarah J; Bellamy William T; Briehl Margaret M; Powis Garth
The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis.
Cancer research 2002;62(17):5089-95.
2001: Kakolyris S; Giatromanolaki A; Koukourakis M; Powis G; Souglakos J; Sivridis E; Georgoulias V; Gatter K C; Harris A L
Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(10):3087-91.
2001: Wipf P; Hopkins T D; Jung J K; Rodriguez S; Birmingham A; Southwick E C; Lazo J S; Powis G
New inhibitors of the thioredoxin-thioredoxin reductase system based on a naphthoquinone spiroketal natural product lead.
Bioorganic & medicinal chemistry letters 2001;11(19):2637-41.
2001: Berggren M I; Husbeck B; Samulitis B; Baker A F; Gallegos A; Powis G
Thioredoxin peroxidase-1 (peroxiredoxin-1) is increased in thioredoxin-1 transfected cells and results in enhanced protection against apoptosis caused by hydrogen peroxide but not by other agents including dexamethasone, etoposide, and doxorubicin.
Archives of biochemistry and biophysics 2001;392(1):103-9.
2001: Xie W; Peng H; Kim D I; Kunkel M; Powis G; Zalkow L H
Structure-activity relationship of aza-steroids as PI-PLC inhibitors.
Bioorganic & medicinal chemistry 2001;9(5):1073-83.
2001: Berggren M M; Powis G
Alternative splicing is associated with decreased expression of the redox proto-oncogene thioredoxin-1 in human cancers.
Archives of biochemistry and biophysics 2001;389(1):144-9.
2001: Rong S B; Hu Y; Enyedy I; Powis G; Meuillet E J; Wu X; Wang R; Wang S; Kozikowski A P
Molecular modeling studies of the Akt PH domain and its interaction with phosphoinositides.
Journal of medicinal chemistry 2001;44(6):898-908.
2001: Tome M E; Baker A F; Powis G; Payne C M; Briehl M M
Catalase-overexpressing thymocytes are resistant to glucocorticoid-induced apoptosis and exhibit increased net tumor growth.
Cancer research 2001;61(6):2766-73.
2001: Peng H; Xie W; Otterness D M; Cogswell J P; McConnell R T; Carter H L; Powis G; Abraham R T; Zalkow L H
Syntheses and biological activities of a novel group of steroidal derived inhibitors for human Cdc25A protein phosphatase.
Journal of medicinal chemistry 2001;44(5):834-48.
2001: Hu Y; Meuillet E J; Berggren M; Powis G; Kozikowski A P
3-Deoxy-3-substituted-D-myo-inositol imidazolyl ether lipid phosphates and carbonate as inhibitors of the phosphatidylinositol 3-kinase pathway and cancer cell growth.
Bioorganic & medicinal chemistry letters 2001;11(2):173-6.
2001: Husbeck B; Berggren M I; Powis G
DNA microarray reveals increased expression of thioredoxin peroxidase in thioredoxin-1 transfected cells and its functional consequences.
Advances in experimental medicine and biology 2001;500():157-68.
2001: Powis G; Montfort W R
Properties and biological activities of thioredoxins.
Annual review of biophysics and biomolecular structure 2001;30():421-55.
2001: Powis G; Montfort W R
Properties and biological activities of thioredoxins.
Annual review of pharmacology and toxicology 2001;41():261-95.
2000: Engman L; Kandra T; Gallegos A; Williams R; Powis G
Water-soluble organotellurium compounds inhibit thioredoxin reductase and the growth of human cancer cells.
Anti-cancer drug design 2000;15(5):323-30.
2000: Powis G; Mustacich D; Coon A
The role of the redox protein thioredoxin in cell growth and cancer.
Free radical biology & medicine 2000;29(3-4):312-22.
2000: Hu Y; Qiao L; Wang S; Rong S B; Meuillet E J; Berggren M; Gallegos A; Powis G; Kozikowski A P
3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth.
Journal of medicinal chemistry 2000;43(16):3045-51.
2000: Freemerman A J; Powis G
A redox-inactive thioredoxin reduces growth and enhances apoptosis in WEHI7.2 cells.
Biochemical and biophysical research communications 2000;274(1):136-41.
2000: Grogan T M; Fenoglio-Prieser C; Zeheb R; Bellamy W; Frutiger Y; Vela E; Stemmerman G; Macdonald J; Richter L; Gallegos A; Powis G
Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival.
Human pathology 2000;31(4):475-81.
2000: Xie W; Peng H; Zalkow L H; Li Y H; Zhu C; Powis G; Kunkel M
3Beta-hydroxy-6-aza-cholestane and related analogues as phosphatidylinositol specific phospholipase C (PI-PLC) inhibitors with antitumor activity.
Bioorganic & medicinal chemistry 2000;8(4):699-706.
2000: Peng H; Xie W; Kim D I; Zalkow L H; Powis G; Otterness D M; Abraham R T
Steroidal derived acids as inhibitors of human Cdc25A protein phosphatase.
Bioorganic & medicinal chemistry 2000;8(2):299-306.
2000: Mustacich D; Powis G
Thioredoxin reductase.
The Biochemical journal 2000;346 Pt 1():1-8.
2000: Baker A; Santos B D; Powis G
Redox control of caspase-3 activity by thioredoxin and other reduced proteins.
Biochemical and biophysical research communications 2000;268(1):78-81.
2000: Qiao L; Hu Y; Nan F; Powis G; Kozikowski A P
A versatile approach to PI(3,4)P2, PI(4,5)P2, and PI(3,4,5)P3 from L-(-)-quebrachitol.
Organic letters 2000;2(2):115-7.
1999: Kirkpatrick D L; Watson S; Kunkel M; Fletcher S; Ulhaq S; Powis G
Parallel syntheses of disulfide inhibitors of the thioredoxin redox system as potential antitumor agents.
Anti-cancer drug design 1999;14(5):421-32.
1999: Yeates L C; Gallegos A; Kozikowski A P; Powis G
Down regulation of the expression of the p110, p85 and p55 subunits of phosphatidylinositol 3-kinase during colon cancer cell anchorage-independent growth.
Anticancer research 1999;19(5B):4171-6.
1999: Gasdaska J R; Harney J W; Gasdaska P Y; Powis G; Berry M J
Regulation of human thioredoxin reductase expression and activity by 3'-untranslated region selenocysteine insertion sequence and mRNA instability elements.
The Journal of biological chemistry 1999;274(36):25379-85.
1999: Freemerman A J; Gallegos A; Powis G
Nuclear factor kappaB transactivation is increased but is not involved in the proliferative effects of thioredoxin overexpression in MCF-7 breast cancer cells.
Cancer research 1999;59(16):4090-4.
1999: Gasdaska P Y; Berggren M M; Berry M J; Powis G
Cloning, sequencing and functional expression of a novel human thioredoxin reductase.
FEBS letters 1999;442(1):105-11.
1999: Berggren M M; Mangin J F; Gasdaka J R; Powis G
Effect of selenium on rat thioredoxin reductase activity: increase by supranutritional selenium and decrease by selenium deficiency.
Biochemical pharmacology 1999;57(2):187-93.
1999: Lemke L E; Paine-Murrieta G D; Taylor C W; Powis G
Wortmannin inhibits the growth of mammary tumors despite the existence of a novel wortmannin-insensitive phosphatidylinositol-3-kinase.
Cancer chemotherapy and pharmacology 1999;44(6):491-7.
1998: Peng H; Zalkow L H; Abraham R T; Powis G
Novel CDC25A phosphatase inhibitors from pyrolysis of 3-alpha-azido-B-homo-6-oxa-4-cholesten-7-one on silica gel.
Journal of medicinal chemistry 1998;41(24):4677-80.
1998: Qiao L; Nan F; Kunkel M; Gallegos A; Powis G; Kozikowski A P
3-Deoxy-D-myo-inositol 1-phosphate, 1-phosphonate, and ether lipid analogues as inhibitors of phosphatidylinositol-3-kinase signaling and cancer cell growth.
Journal of medicinal chemistry 1998;41(18):3303-6.
1998: Powis G; Kirkpatrick D L; Angulo M; Baker A
Thioredoxin redox control of cell growth and death and the effects of inhibitors.
Chemico-biological interactions 1998;111-112():23-34.
1998: Kirkpatrick D L; Kuperus M; Dowdeswell M; Potier N; Donald L J; Kunkel M; Berggren M; Angulo M; Powis G
Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides.
Biochemical pharmacology 1998;55(7):987-94.
1998: Grunicke H H; Powis G
Cell signalling and cancer treatment. AACR special conference in cancer research in collaboration with the British Association for Cancer Research, the German Cancer Society (Section for Experimental Cancer Research), the Austrian Biochemical Society, and the Austrian Cancer Society. 23-28 February 1997, Telfs-Buchen, Austria.
Journal of cancer research and clinical oncology 1998;124(8):462-9.
1997: Kunkel M W; Kirkpatrick D L; Johnson J I; Powis G
Cell line-directed screening assay for inhibitors of thioredoxin reductase signaling as potential anti-cancer drugs.
Anti-cancer drug design 1997;12(8):659-70.
1997: Engman L; Cotgreave I; Angulo M; Taylor C W; Paine-Murrieta G D; Powis G
Diaryl chalcogenides as selective inhibitors of thioredoxin reductase and potential antitumor agents.
Anticancer research 1997;17(6D):4599-605.
1997: Baker A; Payne C M; Briehl M M; Powis G
Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo.
Cancer research 1997;57(22):5162-7.
1997: Andersen J F; Sanders D A; Gasdaska J R; Weichsel A; Powis G; Montfort W R
Human thioredoxin homodimers: regulation by pH, role of aspartate 60, and crystal structure of the aspartate 60 --> asparagine mutant.
Biochemistry 1997;36(46):13979-88.
1997: Gallegos A; Berggren M; Gasdaska J R; Powis G
Mechanisms of the regulation of thioredoxin reductase activity in cancer cells by the chemopreventive agent selenium.
Cancer research 1997;57(21):4965-70.
1997: Berggren M; Gallegos A; Gasdaska J; Powis G
Cellular thioredoxin reductase activity is regulated by selenium.
Anticancer research 1997;17(5A):3377-80.
1997: Yeates L C; Powis G
The expression of the molecular chaperone calnexin is decreased in cancer cells grown as colonies compared to monolayer.
Biochemical and biophysical research communications 1997;238(1):66-70.
1997: Dvorakova K; Dorr R T; Gallegos A; McClure T; Powis G
Pharmacokinetic studies of the herbicide and antitumor compound oryzalin in mice.
Journal of chromatography. B, Biomedical sciences and applications 1997;696(2):275-81.
1997: Powis G; Gallegos A; Abraham R T; Ashendel C L; Zalkow L H; Dorr R; Dvorakova K; Salmon S; Harrison S; Worzalla J
Inhibition of intracellular Ca2+ signalling, cytotoxicity and antitumor activity of the herbicide oryzalin and its analogues.
Cancer chemotherapy and pharmacology 1997;41(1):22-8.
1997: Kirkpatrick D L; Ehrmantraut G; Stettner S; Kunkel M; Powis G
Redox active disulfides: the thioredoxin system as a drug target.
Oncology research 1997;9(6-7):351-6.
1997: Powis G; Gasdaska J R; Gasdaska P Y; Berggren M; Kirkpatrick D L; Engman L; Cotgreave I A; Angulo M; Baker A
Selenium and the thioredoxin redox system: effects on cell growth and death.
Oncology research 1997;9(6-7):303-12.
1997: Powis G; Gasdaska J R; Baker A
Redox signaling and the control of cell growth and death.
Advances in pharmacology (San Diego, Calif.) 1997;38():329-59.
1996: Gasdaska J R; Kirkpatrick D L; Montfort W; Kuperus M; Hill S R; Berggren M; Powis G
Oxidative inactivation of thioredoxin as a cellular growth factor and protection by a Cys73-->Ser mutation.
Biochemical pharmacology 1996;52(11):1741-7.
1996: Gallegos A; Gasdaska J R; Taylor C W; Paine-Murrieta G D; Goodman D; Gasdaska P Y; Berggren M; Briehl M M; Powis G
Transfection with human thioredoxin increases cell proliferation and a dominant-negative mutant thioredoxin reverses the transformed phenotype of human breast cancer cells.
Cancer research 1996;56(24):5765-70.
1996: Berggren M; Gallegos A; Gasdaska J R; Gasdaska P Y; Warneke J; Powis G
Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia.
Anticancer research 1996;16(6B):3459-66.
1996: Gasdaska J R; Gasdaska P Y; Gallegos A; Powis G
Human thioredoxin reductase gene localization to chromosomal position 12q23-q24.1 and mRNA distribution in human tissue.
Genomics 1996;37(2):257-9.
1996: Brunner G; Zalkow L; Burgess E; Rifkin D B; Wilson E L; Gruszecka-Kowalik E; Powis G
Inhibition of glycosylphosphatidylinositol (GPI) phospholipase D by suramin-like compounds.
Anticancer research 1996;16(5A):2513-6.
1996: Weichsel A; Gasdaska J R; Powis G; Montfort W R
Crystal structures of reduced, oxidized, and mutated human thioredoxins: evidence for a regulatory homodimer.
Structure (London, England : 1993) 1996;4(6):735-51.
1996: Baker A F; Briehl M M; Dorr R; Powis G
Decreased antioxidant defence and increased oxidant stress during dexamethasone-induced apoptosis: bcl-2 prevents the loss of antioxidant enzyme activity.
Cell death and differentiation 1996;3(2):207-13.
1996: Glasser L; Dalton W S; Fiederlein R L; Cook P; Powis G; Vogler W R
Response of human multiple myeloma-derived cell lines to alkyl-lysophospholipid.
Experimental hematology 1996;24(2):253-7.
1995: Gasdaska J R; Berggren M; Powis G
Cell growth stimulation by the redox protein thioredoxin occurs by a novel helper mechanism.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1995;6(12):1643-50.
1995: Powis G
Anticancer drugs acting against signaling pathways.
Current opinion in oncology 1995;7(6):554-9.
1995: Gasdaska P Y; Gasdaska J R; Cochran S; Powis G
Cloning and sequencing of a human thioredoxin reductase.
FEBS letters 1995;373(1):5-9.
1995: Powis G; Gasdaska P Y; Gallegos A; Sherrill K; Goodman D
Over-expression of DT-diaphorase in transfected NIH 3T3 cells does not lead to increased anticancer quinone drug sensitivity: a questionable role for the enzyme as a target for bioreductively activated anticancer drugs.
Anticancer research 1995;15(4):1141-5.
1995: Schultz R M; Merriman R L; Andis S L; Bonjouklian R; Grindey G B; Rutherford P G; Gallegos A; Massey K; Powis G
In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin.
Anticancer research 1995;15(4):1135-9.
1995: Frew T; Powis G; Berggren M; Gallegos A; Abraham R T; Ashendel C L; Zalkow L H; Hudson C; Gruszecka-Kowalik E; Burgess E M
Novel quinone antiproliferative inhibitors of phosphatidylinositol-3-kinase.
Anti-cancer drug design 1995;10(4):347-59.
1995: Gasdaska P Y; Fisher H; Powis G
An alternatively spliced form of NQO1 (DT-diaphorase) messenger RNA lacking the putative quinone substrate binding site is present in human normal and tumor tissues.
Cancer research 1995;55(12):2542-7.
1995: Oblong J E; Berggren M; Gasdaska P Y; Hill S R; Powis G
Site-directed mutagenesis of Lys36 in human thioredoxin: the highly conserved residue affects reduction rates and growth stimulation but is not essential for the redox protein's biochemical or biological properties.
Biochemistry 1995;34(10):3319-24.
1995: Powis G; Hill S R; Frew T J; Sherrill K W
Inhibitors of phospholipid intracellular signaling as antiproliferative agents.
Medicinal research reviews 1995;15(2):121-38.
1995: Kozikowski A P; Kiddle J J; Frew T; Berggren M; Powis G
Synthesis and biology of 1D-3-deoxyphosphatidylinositol: a putative antimetabolite of phosphatidylinositol-3-phosphate and an inhibitor of cancer cell colony formation.
Journal of medicinal chemistry 1995;38(7):1053-6.
1995: Briehl M M; Cotgreave I A; Powis G
Downregulation of the antioxidant defence during glucocorticoid-mediated apoptosis.
Cell death and differentiation 1995;2(1):41-6.
1995: Powis G; Berggren M; Gallegos A; Frew T; Hill S; Kozikowski A; Bonjouklian R; Zalkow L; Abraham R; Ashendel C
Advances with phospholipid signalling as a target for anticancer drug development.
Acta biochimica Polonica 1995;42(4):395-403.
1995: Powis G; Briehl M; Oblong J
Redox signalling and the control of cell growth and death.
Pharmacology & therapeutics 1995;68(1):149-73.
1994: Powis G; Workman P
Signalling targets for the development of cancer drugs.
Anti-cancer drug design 1994;9(6):555-68.
1994: Frew T; Powis G; Berggren M; Abraham R T; Ashendel C L; Zalkow L H; Hudson C; Qazia S; Gruszecka-Kowalik E; Merriman R
A multiwell assay for inhibitors of phosphatidylinositol-3-kinase and the identification of natural product inhibitors.
Anticancer research 1994;14(6B):2425-8.
1994: Gasdaska P Y; Oblong J E; Cotgreave I A; Powis G
The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF): thioredoxin mRNA is elevated in some human tumors.
Biochimica et biophysica acta 1994;1218(3):292-6.
1994: Hill S R; Bonjouklian R; Powis G; Abraham R T; Ashendel C L; Zalkow L H
A multisample assay for inhibitors of phosphatidylinositol phospholipase C: identification of naturally occurring peptide inhibitors with antiproliferative activity.
Anti-cancer drug design 1994;9(4):353-61.
1994: Powis G; Workman P
Signalling targets for the development of cancer drugs.
Anti-cancer drug design 1994;9(4):263-77.
1994: Sehgal I; Powers S; Huntley B; Powis G; Pittelkow M; Maihle N J
Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(11):4673-7.
1994: Powis G; Bonjouklian R; Berggren M M; Gallegos A; Abraham R; Ashendel C; Zalkow L; Matter W F; Dodge J; Grindey G
Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase.
Cancer research 1994;54(9):2419-23.
1994: Oblong J E; Berggren M; Gasdaska P Y; Powis G
Site-directed mutagenesis of active site cysteines in human thioredoxin produces competitive inhibitors of human thioredoxin reductase and elimination of mitogenic properties of thioredoxin.
The Journal of biological chemistry 1994;269(16):11714-20.
1994: Oblong J E; Berggren M; Powis G
Biochemical, structural, and biological properties of human thioredoxin active site peptides.
FEBS letters 1994;343(1):81-4.
1994: Powis G
Recent advances in the development of anticancer drugs that act against signalling pathways.
Tumori 1994;80(2):69-87.
1994: Powis G
Signalling pathways as targets for anticancer drug development.
Pharmacology & therapeutics 1994;62(1-2):57-95.
1994: Powis G; Phil D
Inhibitors of phosphatidylinositol signalling as antiproliferative agents.
Cancer metastasis reviews 1994;13(1):91-103.
1994: Oblong J E; Chantler E L; Gallegos A; Kirkpatrick D L; Chen T; Marshall N; Powis G
Reversible inhibition of human thioredoxin reductase activity by cytotoxic alkyl 2-imidazolyl disulfide analogues.
Cancer chemotherapy and pharmacology 1994;34(5):434-8.
1994: Powis G; Gallegos A; Abraham R T; Ashendel C L; Zalkow L H; Grindey G B; Bonjouklian R
Increased intracellular Ca2+ signaling caused by the antitumor agent helenalin and its analogues.
Cancer chemotherapy and pharmacology 1994;34(4):344-50.
1994: Brunn G; Fauq A H; Chow S; Kozikowski A P; Gallegos A; Powis G
Cellular pharmacology of D-3-azido-3-deoxy-myo-inositol, an inhibitor of phosphatidylinositol signaling having antiproliferative activity.
Cancer chemotherapy and pharmacology 1994;35(1):71-9.
1994: Workman P; D'Incalci M; Bursch W; Harrap K R; Hawkins R E; Neidle S; Powis G
European School of Oncology Task Force Report. New approaches in cancer pharmacology: drug design and development (Part 2).
European journal of cancer (Oxford, England : 1990) 1994;30A(8):1148-60.
1994: Powis G; Alberts D S
Inhibiting intracellular signalling as a strategy for cancer chemoprevention.
European journal of cancer (Oxford, England : 1990) 1994;30A(8):1138-44.
1994: Powis G; Oblong J E; Gasdaska P Y; Berggren M; Hill S R; Kirkpatrick D L
The thioredoxin/thioredoxin reductase redox system and control of cell growth.
Oncology research 1994;6(10-11):539-44.
1993: Oblong J E; Powis G
A comment on the absence of calcium regulation of human thioredoxin reductase.
FEBS letters 1993;334(1):1-2.
1993: Gasdaska P Y; Powis G; Hyman P; Fisher H
Cigarette smoking is a determinant of DT-diaphorase gene expression in human non-small cell lung carcinoma.
Cancer research 1993;53(22):5458-61.
1993: Chow S C; Powis G
Mechanisms of platelet-derived growth factor-induced arachidonic acid release in Swiss 3T3 fibroblasts: the role of a localized increase in free Ca2+ concentration beneath the plasma membrane and the activation of protein kinase C.
Biochimica et biophysica acta 1993;1179(1):81-8.
1993: Berggren M I; Gallegos A; Dressler L A; Modest E J; Powis G
Inhibition of the signalling enzyme phosphatidylinositol-3-kinase by antitumor ether lipid analogues.
Cancer research 1993;53(18):4297-302.
1993: Gratas C; Powis G
Inhibition of phospholipase D by agents that inhibit cell growth.
Anticancer research 1993;13(4):1239-44.
1993: Oblong J E; Gasdaska P Y; Sherrill K; Powis G
Purification of human thioredoxin reductase: properties and characterization by absorption and circular dichroism spectroscopy.
Biochemistry 1993;32(28):7271-7.
1993: Berggren M M; Burns L A; Abraham R T; Powis G
Inhibition of protein tyrosine phosphatase by the antitumor agent gallium nitrate.
Cancer research 1993;53(8):1862-6.
1993: Schlager J J; Hoerl B J; Riebow J; Scott D P; Gasdaska P; Scott R E; Powis G
Increased NAD(P)H:(quinone-acceptor)oxidoreductase activity is associated with density-dependent growth inhibition of normal but not transformed cells.
Cancer research 1993;53(6):1338-42.
1993: Iaizzo P A; Seewald M J; Powis G; Van Dyke R A
The effects of sevoflurane on intracellular Ca2+ regulation in rat hepatocytes.
Toxicology letters 1993;66(1):81-8.
1992: Powis G
Drugs active against growth factor and oncogene phosphatidylinositol signalling pathways.
Seminars in cancer biology 1992;3(6):343-50.
1992: Chapman D E; Michener S R; Powis G
Metabolism of 2,6-dinitro[3-3H]toluene by human and rat liver microsomal and cytosolic fractions.
Xenobiotica; the fate of foreign compounds in biological systems 1992;22(8):1015-28.
1992: Powis G; Seewald M J; Gratas C; Melder D; Riebow J; Modest E J
Selective inhibition of phosphatidylinositol phospholipase C by cytotoxic ether lipid analogues.
Cancer research 1992;52(10):2835-40.
1992: Mau B L; Powis G
Inhibition of cellular thioredoxin reductase by diaziquone and doxorubicin. Relationship to the inhibition of cell proliferation and decreased ribonucleotide reductase activity.
Biochemical pharmacology 1992;43(7):1621-7.
1992: Mau B L; Powis G
Mechanism-based inhibition of thioredoxin reductase by antitumor quinoid compounds.
Biochemical pharmacology 1992;43(7):1613-20.
1992: Powis G; Seewald M J; Melder D; Hoke M; Gratas C; Christensen T A; Chapman D E
Inhibition of growth factor binding, Ca2+ signaling and cell growth by polysulfonated azo dyes related to the antitumor agent suramin.
Cancer chemotherapy and pharmacology 1992;31(3):223-8.
1992: Powis G; Seewald M; Hoke M
Inhibition of growth factor binding and intracellular Ca2+ signalling by dextran sulfates of different sizes and degrees of sulfation.
Cancer chemotherapy and pharmacology 1992;30(6):483-6.
1991: Powis G; Kozikowski A
Growth factor and oncogene signalling pathways as targets for rational anticancer drug development.
Clinical biochemistry 1991;24(5):385-97.
1991: Chapman D E; Michener S R; Powis G
Metabolism of the flame retardant plasticizer tris(2-chloroethyl)phosphate by human and rat liver preparations.
Fundamental and applied toxicology : official journal of the Society of Toxicology 1991;17(2):215-24.
1991: Powis G
Signalling targets for anticancer drug development.
Trends in pharmacological sciences 1991;12(5):188-94.
1991: Iaizzo P A; Seewald M J; Olsen R; Wedel D J; Chapman D E; Berggren M; Eichinger H M; Powis G
Enhanced mobilization of intracellular Ca2+ induced by halothane in hepatocytes isolated from swine susceptible to malignant hyperthermia.
Anesthesiology 1991;74(3):531-8.
1991: Olsen R A; Seewald M J; Melder D C; Berggren M; Iaizzo P A; Powis G
Platelet-derived growth factor blocks the increase in intracellular free Ca2+ caused by calcium ionophores and a volatile anesthetic agent in Swiss 3T3 fibroblasts without altering toxicity.
Toxicology letters 1991;55(1):117-25.
1991: Chapman D E; Powis G
Disposition and metabolism in mice of the potential antitumor and anti-human immunodeficiency virus-1 agent, 2-chloro-2',3'-dideoxyadenosine.
Cancer chemotherapy and pharmacology 1991;27(4):285-9.
1991: Powis G; Aksoy I A; Melder D C; Aksoy S; Eichinger H; Fauq A H; Kozikowski A P
D-3-deoxy-3-substituted myo-inositol analogues as inhibitors of cell growth.
Cancer chemotherapy and pharmacology 1991;29(2):95-104.
1990: Forrester L M; Hayes J D; Millis R; Barnes D; Harris A L; Schlager J J; Powis G; Wolf C R
Expression of glutathione S-transferases and cytochrome P450 in normal and tumor breast tissue.
Carcinogenesis 1990;11(12):2163-70.
1990: Secrist J P; Sehgal I; Powis G; Abraham R T
Preferential inhibition of the platelet-derived growth factor receptor tyrosine kinase by staurosporine.
The Journal of biological chemistry 1990;265(33):20394-400.
1990: Chapman D E; Moore T J; Michener S R; Powis G
Metabolism and covalent binding of [14C]toluene by human and rat liver microsomal fractions and liver slices.
Drug metabolism and disposition: the biological fate of chemicals 1990;18(6):929-36.
1990: Iaizzo P A; Olsen R A; Seewald M J; Powis G; Stier A; Van Dyke R A
Transient increases of intracellular Ca2+ induced by volatile anesthetics in rat hepatocytes.
Cell calcium 1990;11(8):515-24.
1990: Seewald M J; Olsen R A; Sehgal I; Melder D C; Modest E J; Powis G
Inhibition of growth factor-dependent inositol phosphate Ca2+ signaling by antitumor ether lipid analogues.
Cancer research 1990;50(15):4458-63.
1990: Powis G; Seewald M J; Sehgal I; Iaizzo P A; Olsen R A
Platelet-derived growth factor stimulates non-mitochondrial Ca2+ uptake and inhibits mitogen-induced Ca2+ signaling in Swiss 3T3 fibroblasts.
The Journal of biological chemistry 1990;265(18):10266-73.
1990: Oakes S G; Schlager J J; Santone K S; Abraham R T; Powis G
Doxorubicin blocks the increase in intracellular Ca++, part of a second messenger system in N1E-115 murine neuroblastoma cells.
The Journal of pharmacology and experimental therapeutics 1990;252(3):979-83.
1990: Powis G; Olsen R; Standing J E; Kachel D; Martin W J
Amiodarone-mediated increase in intracellular free Ca2+ associated with cellular injury to human pulmonary artery endothelial cells.
Toxicology and applied pharmacology 1990;103(1):156-64.
1990: Howie A F; Forrester L M; Glancey M J; Schlager J J; Powis G; Beckett G J; Hayes J D; Wolf C R
Glutathione S-transferase and glutathione peroxidase expression in normal and tumour human tissues.
Carcinogenesis 1990;11(3):451-8.
1990: Olsen R; Melder D; Seewald M; Abraham R; Powis G
Staurosporine inhibition of intracellular free Ca2+ transients in mitogen-stimulated Swiss 3T3 fibroblasts.
Biochemical pharmacology 1990;39(5):968-72.
1990: Iaizzo P A; Seewald M J; Powis G; Van Dyke R A
The effects of volatile anesthetics on Ca++ mobilization in rat hepatocytes.
Anesthesiology 1990;72(3):504-9.
1990: Schlager J J; Powis G
Cytosolic NAD(P)H:(quinone-acceptor)oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol.
International journal of cancer. Journal international du cancer 1990;45(3):403-9.
1990: Seewald M J; Olsen R A; Powis G
Suramin blocks intracellular Ca2+ release and growth factor-induced increases in cytoplasmic free Ca2+ concentration.
Cancer letters 1990;49(2):107-13.
1990: Brodfuehrer J I; Chapman D E; Wilke T J; Powis G
Comparative studies of the in vitro metabolism and covalent binding of 14C-benzene by liver slices and microsomal fraction of mouse, rat, and human.
Drug metabolism and disposition: the biological fate of chemicals 1990;18(1):20-7.
1990: Mau B L; Powis G
Inhibition of thioredoxin reductase (E.C. 1.6.4.5.) by antitumor quinones.
Free radical research communications 1990;8(4-6):365-72.
1989: Moore D J; Batts K P; Zalkow L L; Fortune G T; Powis G
Model systems for detecting the hepatic toxicity of pyrrolizidine alkaloids and pyrrolizidine alkaloid N-oxides.
Toxicology and applied pharmacology 1989;101(2):271-84.
1989: Workman P; Walton M I; Powis G; Schlager J J
DT-diaphorase: questionable role in mitomycin C resistance, but a target for novel bioreductive drugs?
British journal of cancer 1989;60(5):800-2; discussion 803.
1989: Wilke T J; Jondorf W R; Powis G
Oxidative metabolism of 14C-pyridine by human and rat tissue subcellular fractions.
Xenobiotica; the fate of foreign compounds in biological systems 1989;19(9):1013-22.
1989: Powis G; Melder D C; Wilke T J
Human and dog, but not rat, isolated hepatocytes have decreased foreign compound-metabolizing activity compared to liver slices.
Drug metabolism and disposition: the biological fate of chemicals 1989;17(5):526-31.
1989: Olsen R; Seewald M; Powis G
Contribution of external and internal Ca2+ to changes in intracellular free Ca2+ produced by mitogens in Swiss 3T3 fibroblasts: the role of dihydropyridine sensitive Ca2+ channels.
Biochemical and biophysical research communications 1989;162(1):448-55.
1989: Frazier J M; Tyson C A; McCarthy C; McCormick J J; Meyer D; Powis G; Ducat L
Potential use of human tissues for toxicity research and testing.
Toxicology and applied pharmacology 1989;97(3):387-97.
1989: Santone K S; Melder D C; Powis G
Studies of chemical toxicity to fresh and cryopreserved rat hepatocytes.
Toxicology and applied pharmacology 1989;97(2):370-6.
1989: Kooistra K L; Rodriguez M; Powis G
Toxicity of intrathecally administered cytotoxic drugs and their antitumor activity against an intrathecal Walker 256 carcinosarcoma model for meningeal carcinomatosis in the rat.
Cancer research 1989;49(4):977-82.
1989: Brodfuehrer J I; Wilke T J; Kinder D H; Powis G
Preclinical pharmacologic studies of the new antitumor agent carmethizole (NSC-602668) in the mouse and beagle dog.
Cancer chemotherapy and pharmacology 1989;24(5):277-83.
1989: Powis G
The use of human liver for foreign compound metabolism and toxicity studies.
Drug metabolism reviews 1989;20(2-4):379-94.
1989: Chapman D E; Moore D J; Melder D C; Breau A; Powis G
Isolation, identification and biological activity of a phyllanthoside metabolite produced in vitro by mouse plasma.
Cancer chemotherapy and pharmacology 1989;25(3):184-8.
1989: Powis G
Free radical formation by antitumor quinones.
Free radical biology & medicine 1989;6(1):63-101.
1989: Seewald M J; Schlager J J; Olsen R A; Melder D C; Powis G
High molecular weight dextran sulfate inhibits intracellular Ca2+ release and decreases growth factor-induced increases in intracellular free Ca2+ in Swiss 3T3 fibroblasts.
Cancer communications 1989;1(3):151-6.
1988: Olsen R; Santone K; Melder D; Oakes S G; Abraham R; Powis G
An increase in intracellular free Ca2+ associated with serum-free growth stimulation of Swiss 3T3 fibroblasts by epidermal growth factor in the presence of bradykinin.
The Journal of biological chemistry 1988;263(34):18030-5.
1988: Windebank K P; Abraham R T; Powis G; Olsen R A; Barna T J; Leibson P J
Signal transduction during human natural killer cell activation: inositol phosphate generation and regulation by cyclic AMP.
Journal of immunology (Baltimore, Md. : 1950) 1988;141(11):3951-7.
1988: Oakes S G; Iaizzo P A; Richelson E; Powis G
Histamine-induced intracellular free Ca++, inositol phosphates and electrical changes in murine N1E-115 neuroblastoma cells.
The Journal of pharmacology and experimental therapeutics 1988;247(1):114-21.
1988: Zalkow L H; Glinski J A; Gelbaum L T; Moore D; Melder D; Powis G
Semisynthetic pyrrolizidine alkaloid N-oxide antitumor agents. Esters of heliotridine.
Journal of medicinal chemistry 1988;31(8):1520-6.
1988: Zalkow L H; Asibal C F; Glinski J A; Bonetti S J; Gelbaum L T; VanDerveer D; Powis G
Macrocyclic pyrrolizidine alkaloids from Senecio anonymus. Separation of a complex alkaloid extract using droplet counter-current chromatography.
Journal of natural products 1988;51(4):690-702.
1988: Powis G; Jardine I; Van Dyke R; Weinshilboum R; Moore D; Wilke T; Rhodes W; Nelson R; Benson L; Szumlanski C
Foreign compound metabolism studies with human liver obtained as surgical waste. Relation to donor characteristics and effects of tissue storage.
Drug metabolism and disposition: the biological fate of chemicals 1988;16(4):582-9.
1988: Brodfuehrer J I; Powis G
Gas chromatographic assay for the new antitumor agent sulfamic acid diester (NSC 329680) and its stability in buffer, blood and plasma.
Journal of chromatography 1988;427(2):247-55.
1988: Brodfüehrer J I; Moore D J; Melder D C; Wilke T J; Powis G
In vitro cytotoxicity of pyrazine-2-diazohydroxide: specificity for hypoxic cells and effects of microsomal coincubation.
Investigational new drugs 1988;6(1):3-9.
1988: Southorn P A; Powis G
Free radicals in medicine. II. Involvement in human disease.
Mayo Clinic proceedings. Mayo Clinic 1988;63(4):390-408.
1988: Southorn P A; Powis G
Free radicals in medicine. I. Chemical nature and biologic reactions.
Mayo Clinic proceedings. Mayo Clinic 1988;63(4):381-9.
1988: Oakes S G; Martin W J; Lisek C A; Powis G
Incomplete hydrolysis of the calcium indicator precursor fura-2 pentaacetoxymethyl ester (fura-2 AM) by cells.
Analytical biochemistry 1988;169(1):159-66.
1988: Brodfuehrer J I; Wilke T J; Powis G
Pharmacokinetics and metabolism of the antitumor agent sulfamic acid 1,7-heptanediyl ester (sulfamic acid diester) in the mouse and beagle dog.
Cancer chemotherapy and pharmacology 1988;22(2):120-5.
1988: Moore D J; Brodfuehrer J I; Wilke T J; Powis G
Disposition and metabolism of the antitumor agent pyrazine-2-diazohydroxide in mouse and beagle dog.
Cancer chemotherapy and pharmacology 1988;21(4):269-73.
1988: Schlager J J; Powis G
Mitomycin C is not metabolized by but is an inhibitor of human kidney NAD(P)H: (quinone-acceptor)oxidoreductase.
Cancer chemotherapy and pharmacology 1988;22(2):126-30.
1987: Powis G; Moore D J; Wilke T J; Santone K S
A high-performance liquid chromatography assay for measuring integrated biphenyl metabolism by intact cells: its use with rat liver and human liver and kidney.
Analytical biochemistry 1987;167(1):191-8.
1987: Powis G; Santone K S; Melder D C; Thomas L; Moore D J; Wilke T J
Cryopreservation of rat and dog hepatocytes for studies of xenobiotic metabolism and activation.
Drug metabolism and disposition: the biological fate of chemicals 1987;15(6):826-32.
1987: Powis G; See K L; Santone K S; Melder D C; Hodnett E M
Quinoneimines as substrates for quinone reductase (NAD(P)H: (quinone-acceptor)oxidoreductase) and the effect of dicumarol on their cytotoxicity.
Biochemical pharmacology 1987;36(15):2473-9.
1987: Oakes S G; Santone K S; Powis G
Effect of some anticancer drugs on the surface membrane electrical properties of differentiated murine neuroblastoma cells.
Journal of the National Cancer Institute 1987;79(1):155-61.
1987: Long H J; Powis G; Schutt A J; Moertel C G
Phase I and pharmacokinetic study of menogaril administered as a 72-hour continuous i.v. infusion.
Cancer treatment reports 1987;71(6):593-8.
1987: Powis G; Hodnett E M; Santone K S; See K L; Melder D C
Role of metabolism and oxidation-reduction cycling in the cytotoxicity of antitumor quinoneimines and quinonediimines.
Cancer research 1987;47(9):2363-70.
1987: Van Dyke R A; Kooistra K L; Moses C J; Powis G
Effect of inhalation anesthetics on antipyrine pharmacokinetics of mice.
Biochemical pharmacology 1987;36(7):1023-7.
1987: Powis G; Kooistra K L
Doxorubicin-induced hair loss in the Angora rabbit: a study of treatments to protect against the hair loss.
Cancer chemotherapy and pharmacology 1987;20(4):291-6.
1987: Powis G
Metabolism and reactions of quinoid anticancer agents.
Pharmacology & therapeutics 1987;35(1-2):57-162.
1987: Powis G; Reece P; Ahmann D L; Ingle J N
Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients.
Cancer chemotherapy and pharmacology 1987;20(3):219-22.
1986: Wilke T J; Kooistra K L; Moore D J; Powis G
Gas chromatographic assay for the new antitumor agent pyrazine-2-diazohydroxide (diazohydroxide) and its stability in buffer, blood and plasma.
Journal of chromatography 1986;383(1):77-83.
1986: Santone K S; Oakes S G; Taylor S R; Powis G
Anthracycline-induced inhibition of a calcium action potential in differentiated murine neuroblastoma cells.
Cancer research 1986;46(6):2659-64.
1986: Santone K S; Kroschel D M; Powis G
Enhanced formation of ethane and n-pentane by rat hepatocytes in the presence of dimethyl sulfoxide.
Biochemical pharmacology 1986;35(8):1287-92.
1986: Powis G; Basseches P J; Kroschel D M; Richardson R L; O'Connell M J; Kvols L K
Disposition of tricyclic nucleoside-5'-monophosphate in blood and plasma of patients during phase I and II clinical trials.
Cancer treatment reports 1986;70(3):359-62.
1986: Kooistra K L; Rodriguez M; Powis G; Yaksh T L; Harty G J; Hilton J F; Laws E R
Development of experimental models for meningeal neoplasia using intrathecal injection of 9L gliosarcoma and Walker 256 carcinosarcoma in the rat.
Cancer research 1986;46(1):317-23.
1986: Powis G; Harris R N; Basseches P J; Santone K S
Effects of advanced leukemia on hepatic drug-metabolizing activity in the mouse.
Cancer chemotherapy and pharmacology 1986;16(1):43-9.
1986: Rosenow S; Kooistra K L; Powis G; Van Dyke R A
Increased toxicity of the antitumor drug cyclophosphamide in mice in the presence of the volatile anesthetic agent halothane.
Cancer chemotherapy and pharmacology 1986;16(1):35-42.
1986: Appel P L; Alley M C; Lieber M M; Shoemaker R; Powis G
Metabolic stability of experimental chemotherapeutic agents in hepatocyte:tumor cell co-cultures.
Cancer chemotherapy and pharmacology 1986;17(1):47-52.
1986: Moore D J; Powis G
Disposition and metabolism of the antitumor glycoside phyllanthoside in mouse and beagle dog.
Cancer chemotherapy and pharmacology 1986;16(3):218-22.
1985: Powis G; Kroschel D M; Moore D J
Sensitive reversed-phase high-performance liquid chromatographic assay for the antitumor agent benzisoquinolinedione (Nafidimide) employing direct on-column injection of plasma and urine, and its use for pharmacokinetic studies in a dog.
Journal of chromatography 1985;345(2):402-7.
1985: Moore D J; Powis G; Richardson R L; Pittelkow M R
Topical chemotherapy of intradermal Walker 256 carcinosarcoma with diaziquone and doxorubicin in the rat.
Cancer research 1985;45(11 Pt 1):5466-72.
1985: Powis G; Moore D J
High-performance liquid chromatographic assay for the antitumor glycoside phyllanthoside and its stability in plasma of several species.
Journal of chromatography 1985;342(1):129-34.
1985: Martin W J; Powis G W; Kachel D L
Nitrofurantoin-stimulated oxidant production in pulmonary endothelial cells.
The Journal of laboratory and clinical medicine 1985;105(1):23-9.
1985: Powis G
Anticancer drug pharmacodynamics.
Cancer chemotherapy and pharmacology 1985;14(3):177-83.
1984: Basseches P J; Powis G
Metabolism and disposition of 3-amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6, 8-pentaazaacenaphthylene in the rat.
Cancer research 1984;44(9):3672-8.
1984: Powis G; Svingen B A; Dahlin D C; Nelson S D
Enzymatic and non-enzymatic reduction of N-acetyl-p-benzoquinone imine and some properties of the N-acetyl-p-benzosemiquinone imine radical.
Biochemical pharmacology 1984;33(15):2367-70.
1984: Reece P A; McCall J T; Powis G; Richardson R L
Sensitive high-performance liquid chromatographic assay for platinum in plasma ultrafiltrate.
Journal of chromatography 1984;306():417-23.
1984: Alley M C; Powis G; Appel P L; Kooistra K L; Lieber M M
Activation and inactivation of cancer chemotherapeutic agents by rat hepatocytes cocultured with human tumor cell lines.
Cancer research 1984;44(2):549-56.
1984: Harris R N; Basseches P J; Appel P L; Durski A M; Powis G
Carbon tetrachloride-induced increase in the antitumor activity of cyclophosphamide in mice: a pharmacokinetic study.
Cancer chemotherapy and pharmacology 1984;12(3):167-72.
1983: Powis G; Kovach J S
Disposition of bisantrene in humans and rabbits: evidence for intravascular deposition of drug as a cause of phlebitis.
Cancer research 1983;43(2):925-9.
1983: Powis G
Dose-dependent metabolism, therapeutic effect, and toxicity of anticancer drugs in man.
Drug metabolism reviews 1983;14(6):1145-63.
1982: Basseches P J; Durski A; Powis G
High-performance liquid chromatographic assay of the antineoplastic agent tricyclic nucleoside 5'-phosphate and its disposition in rabbit.
Journal of chromatography 1982;233():227-34.
1982: Hartman N; Basseches P J; Powis G
Effect of cyclophosphamide pretreatment on the short-term disposition and biliary excretion of adriamycin metabolites in rat.
Cancer chemotherapy and pharmacology 1982;10(1):11-5.
1982: Powis G
Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs.
Cancer treatment reviews 1982;9(2):85-124.
1982: Eagan R T; Ames M M; Powis G; Kovach J S
Clinical and pharmacologic evaluation of split-dose intermittent therapy with dianhydrogalactitol.
Cancer treatment reports 1982;66(2):283-7.
1982: Powis G; Svingen B A; Degraw C
Iron-EDTA stimulated reduction of indicine N-oxide by the hepatic microsomal fraction, isolated hepatocytes, and the intact rat.
Biochemical pharmacology 1982;31(3):293-9.
1982: O'Connell M J; Powis G; Rubin J; Moertel C G
Pilot study of PALA and 5-FU in patients with advanced cancer.
Cancer treatment reports 1982;66(1):77-80.
1981: Powis G
Reversed-phase high-performance liquid chromatographic assay for the antineoplastic agent 9,10-anthracenedicarboxaldehyde bis(4,5-dihydro-1H-imidazol-2-yl hydrazone) dihydrochloride.
Journal of chromatography 1981;226(2):514-20.
1981: Kovach J S; Eagan R T; Powis G; Rubin J; Creagan E T; Moertel C G
Phase I and pharmacokinetic studies of DON.
Cancer treatment reports 1981;65(11-12):1031-6.
1981: Svingen B A; Powis G; Appel P L; Scott M
Protection against adriamycin-induced skin necrosis in the rat by dimethyl sulfoxide and alpha-tocopherol.
Cancer research 1981;41(9 Pt 1):3395-9.
1981: Powis G; Svingen B A; Appel P
Quinone-stimulated superoxide formation by subcellular fractions, isolated hepatocytes, and other cells.
Molecular pharmacology 1981;20(2):387-94.
1981: Svingen B A; Powis G
Pulse radiolysis studies of antitumor quinones: radical lifetimes, reactivity with oxygen, and one-electron reduction potentials.
Archives of biochemistry and biophysics 1981;209(1):119-26.
1981: Svingen B A; Powis G; Appel P L; Scott M
Protection by alpha-tocopherol and dimethylsulfoxide (DMSO) against adriamycin induced skin ulcers in the rat.
Research communications in chemical pathology and pharmacology 1981;32(1):189-92.
1981: Powis G; Kovach J S
Binding of copper and zinc by the antitumour agent L-alanosine.
Biochemical pharmacology 1981;30(7):771-6.
1981: Letendre L; Smithson W A; Gilchrist G S; Burgert E O; Hoagland C H; Ames M M; Powis G; Kovach J S
Activity of indicine N-oxide in refractory acute leukemia.
Cancer 1981;47(3):437-41.
1981: Lieber M M; Ames M M; Powis G; Kovach J S
Anticancer drug testing in vitro: use of an activating system with the human tumor stem cell assay.
Life sciences 1981;28(3):287-93.
1981: Powis G; Ames M M; Kovach J S
Dose-dependent pharmacokinetics and cancer chemotherapy.
Cancer chemotherapy and pharmacology 1981;6(1):1-9.
1981: Powis G; Svingen B A; Appel P
Factors affecting the intracellular generation of free radicals from quinones.
Advances in experimental medicine and biology 1981;136 Pt A():349-58.
1980: Powis G; Appel P L
Relationship of the single-electron reduction potential of quinones to their reduction by flavoproteins.
Biochemical pharmacology 1980;29(19):2567-72.
1980: Powis G; DeGraw C L
N-Oxide reduction by hemoglobin, cytochrome C and ferrous ions.
Research communications in chemical pathology and pharmacology 1980;30(1):143-50.
1980: Moore E D; Powis G
Plasma and tissue concentrations of hycanthone in the mouse determined by reversed-phase high-performance liquid chromatography.
Journal of chromatography 1980;183(3):372-7.
1980: Powis G; Wincentsen L
Pyridine nucleotide cofactor requirements of indicine N-oxide reduction by hepatic microsomal cytochrome P-450.
Biochemical pharmacology 1980;29(3):347-51.
1980: Powis G; Ames M M
Determination of 6-diazo-5-oxo-L-norleucine in plasma and urine by reversed-phase high-performance liquid chromatography of the dansyl derivative.
Journal of chromatography 1980;181(1):95-9.
1979: Ames M M; Powis G; Kovach J S; Eagan R T
Disposition and metabolism of pentamethylmelamine and hexamethylmelamine in rabbits and humans.
Cancer research 1979;39(12):5016-21.
1979: Kovach J S; Ames M M; Powis G; Moertel C G; Hahn R G; Creagan E T
Toxicity and pharmacokinetics of a pyrrolizidine alkaloid, indicine N-oxide, in humans.
Cancer research 1979;39(11):4540-4.
1979: Powis G; Ames M M; Kovach J S
Metabolic conversion of indicine N-oxide to indicine in rabbits and humans.
Cancer research 1979;39(9):3564-70.
1979: Powis G; Ames M M; Kovach J S
Relationship of the reductive metabolism of indicine N-oxide to its antitumor activity.
Research communications in chemical pathology and pharmacology 1979;24(3):559-69.
1979: Ames M M; Powis G
Determination of pentamethylmelamine and hexamethylmelamine in plasma and urine by nitrogen-phosphorus gas-liquid chromatography.
Journal of chromatography 1979;174(1):245-9.
1979: Schenkman J B; Jansson I; Powis G; Kappus H
Active oxygen in liver microsomes: mechanism of epinephrine oxidation.
Molecular pharmacology 1979;15(2):428-38.
1979: Powis G; Ames M M
Determination of L-alanosine in plasma and urine by reversed-phase high-performance liquid chromatography of the Dns derivative.
Journal of chromatography 1979;170(1):195-201.
1979: Ames M M; Powis G; Kuehn P
Determination of pyrazoloimidazole in plasma and urine by gas-liquid chromatography using nitrogen-phosphorus detection.
Journal of chromatography 1979;169():412-5.
1979: Powis G; Jansson I
Stoichiometry of the mixed function oxidase.
Pharmacology & therapeutics 1979;7(2):297-311.
1979: Powis G
Hepatic microsomal metabolism of epinephrine and adrenochrome by superoxide-dependent and -independent pathways.
Biochemical pharmacology 1979;28(1):83-9.
1978: Ames M M; Powis G
Determination of indicine N-oxide and indicine in plasma and urine by electron-capture gas-liquid chromatography.
Journal of chromatography 1978;166(2):519-26.
1978: Powis G; Snow D H
The effects of exercise and adrenaline infusion upon the blood levels of propranolol and antipyrine in the horse.
The Journal of pharmacology and experimental therapeutics 1978;205(3):725-31.
1978: Khoyi M A; Pousti A; Powis G; Zarrindast M R
Tachyphylaxis to ethacrynic acid in the isolated atrium of guinea-pig and its relation to noradrenaline stores.
British journal of pharmacology 1978;63(1):191-6.
1977: Powis G; Cummings J; Morgan E
The effect of adrenalectomy upon the absorption, distribution and metabolism of ethanol in the rat.
Life sciences 1977;21(7):1033-6.
1977: Blumgart L H; Harper A M; Leiberman D P; Mathie R T; Powis G
Liver blood flow measurements with 85kripton clearance by portal venous and hepatic arterial routes of injection [proceedings]
British journal of pharmacology 1977;60(2):278P.
1977: Mabrey S; Powis G; Schenkman J B; Tritton T R
Calorimetric study of microsomal membrane.
The Journal of biological chemistry 1977;252(9):2929-33.
1977: Powis G
Drug clearance in the rabbit twenty-four hours after an intoxicating dose of ethanol [proceedings].
British journal of pharmacology 1977;59(3):490P-491P.
1977: Powis G; Jansson I; Schenkman J B
The effects of albumin upon the spectral changes and metabolism by the hepatic microsomal fraction.
Archives of biochemistry and biophysics 1977;179(1):34-42.
1977: Powis G; Lyon L; McKillop D
NADH synergism of microsomal aniline metabolism in the presence of enhancing agents.
Biochemical pharmacology 1977;26(2):137-41.
1976: Powis G; Grant L
The effect of inhibitors of alcohol metabolism upon the changes in the hepatic microsomal metabolism of foreign compounds produced by the acute administration of some alcohols to the rat.
Biochemical pharmacology 1976;25(19):2197-201.
1976: McKillop D; Powis G
The metabolism and binding of catecholamines by the hepatic microsomal mixed-function oxidase of the rat.
The Biochemical journal 1976;158(1):135-40.
1976: Grant L; Powis G
Proceedings: The effect of inhibitors of alcohol metabolism on the changes in the hepatic microsomal metabolism of foreign compounds produced by a single dose of ethanol in the rat.
British journal of pharmacology 1976;56(3):376P-377P.
1976: Powis G; Drummond A H; Macintyre D E; Jondorf W R
Development of liver microsomal oxidations in the chick.
Xenobiotica; the fate of foreign compounds in biological systems 1976;6(2):69-81.
1976: McKillop D; Powis G
The metabolism and binding of catecholamines by the hepatic microsomal fraction of the rat.
Biochemical Society transactions 1976;4(1):145-7.
1975: Powis G
The binding of catecholamines to the serum proteins of the rat and the domestic fowl.
Comparative biochemistry and physiology. C: Comparative pharmacology 1975;52(2):85-90.
1975: Powis G; Boobis A R
Effect of washing the hepatic microsomal fraction in sucrose solutions and in sucrose solution containing EDTA upon the metabolism of foreign compounds.
Biochemical pharmacology 1975;24(19):1771-6.
1975: Powis G
Effect of a single oral dose of methanol, ethanol and propan-2-ol on the hepatic microsomal metabolism of foreign compounds in the rat.
The Biochemical journal 1975;148(2):269-77.
1975: McKillop D; Powis G
The effect of a single dose of ethanol on the hepatic microsomal metabolism of foreign compounds in the rat.
British journal of pharmacology 1975;53(3):442P.
1975: Powis G
The binding of catecholamines to human serum proteins.
Biochemical pharmacology 1975;24(6):707-12.
1975: Boobis A R; Powis G
The metabolism and disposition of aniline in the isolated blood-perfused liver of the rat.
Drug metabolism and disposition: the biological fate of chemicals 1975;3(2):63-8.
1975: Powis G; Boobis A R
The effect of pretreating rats with 3-methylcholanthrene upon the enhancement of microsomal aniline hydroxylation by acetone and other agents.
Biochemical pharmacology 1975;24(3):424-6.
1974: Boobis A R; Powis G
The effects of catecholamines upon the metabolism of foreign compounds and upon the distribution of perfusate in the isolated liver of the rat.
Biochemical pharmacology 1974;23(24):3377-84.
1974: Powis G
Effect of serum albumin upon the response of the rat isolated superfused anococcygeus muscle to catecholamines and to nerve stimulation.
The Journal of pharmacy and pharmacology 1974;26(5):344-7.
1974: Blakeley A G; Powis G; Summers R J
An uptake mechanism for L-noradrenaline in the cat spleen, associated with the nerves but distinct from uptake.
The Journal of physiology 1974;238(1):193-206.
1974: Clark H; Powis G
Effect of acetone administered in vivo upon hepatic microsomal drug metabolizing activity in the rat.
Biochemical pharmacology 1974;23(5):1015-9.
1974: Powis G
A study of the interaction of tetracycline with human serum lipoproteins and albumin.
The Journal of pharmacy and pharmacology 1974;26(2):113-8.
1973: Blakeley A G; Powis G; Summers R J
Proceedings: Uptake of (L)-noradrenaline in the isolated cat heart perfused with blood containing desmethylimipramine (DMI) and 17-beta-oestradiol (17beta0).
The Journal of physiology 1973;234(2):108P-109P.
1973: Powis G
Binding of catecholamines to connective tissue and the effect upon the responses of blood vessels to noradrenaline and to nerve stimulation.
The Journal of physiology 1973;234(1):145-62.
1973: Boobis A; Powis G
Proceedings: The isolated perfused rat liver in the study of the metabolism of foreign compounds.
British journal of pharmacology 1973;49(1):185P-186P.
1973: Blakeley A G; Powis G; Summers R J
The effects of pargyline on overflow of transmitter and uptake of noradrenaline in the cat spleen.
British journal of pharmacology 1973;47(4):719-28.
1973: Powis G
The accumulation and metabolism of (-)-noradrenaline by cells in culture.
British journal of pharmacology 1973;47(3):568-75.
1973: Blakeley A G; Powis G; Summers R J
Some characteristics of the uptake process in the isolated blood perfused cat spleen resistant to desmethylimipramine and 17- -oestradiol.
British journal of pharmacology 1973;47(3):634P-635P.
1973: Jondorf W R; MacIntyre D E; Powis G
Induction of liver microsomal drug metabolism in newly-hatched chicks.
British journal of pharmacology 1973;47(3):624P-625P.
1973: Blakeley A G; Powis G; Summers R J
An uptake process for L-noradrenaline resistant to desmethylimipramine (DMI) and 17 -estradiol in the cat spleen.
The Journal of physiology 1973;229(1):31P-32P.
1971: Blakeley A G; Powis G; Summers R J
Effect of the monoamine oxidase inhibitor pargyline on the uptake of labelled noradrenaline by the cat's spleen.
British journal of pharmacology 1971;43(2):451P-452P.
1971: Parsons D S; Powis G
Some properties of a preparation of rat colon perfused in vitro through the vascular bed.
The Journal of physiology 1971;217(3):641-63.
1970: Powis G
Perfusion of rat's liver with blood: transmitter overflows and gluconeogenesis.
Proceedings of the Royal Society of London. Series B, Containing papers of a Biological character. Royal Society (Great Britain) 1970;174(37):503-15.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Garth Powis

Research Profile (preview)

Chemicals & Drugs

Living Beings

Anatomy

Physiology

Phenomena

Disorders

Concepts & Ideas

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Garth Powis (preview)

All Publications